News

Show
news from

OMass Therapeutics Announces Appointment of New Board Chair and Series B Extension

OMass Therapeutics Announces New Phase of Growth with Move to New Facilities and Team Expansion to Support Portfolio Progress

Mosaic Therapeutics closes $28m series A funding and appoints Brian Gladsden as CEO

Publication in Nature Chemistry Demonstrates the Benefits of Native Mass Spectrometry in the Interrogation of Target Ecosystems and Drug Discovery

OMass Therapeutics Raises $100 Million in Series B Financing to Progress Drug Pipeline in Immunology and Rare Diseases

OMass CEO Ros Deegan Named as a 2022 In Vivo Rising Leader

Load more

Search